@entity1037 is an 'atypical' antipsychotic indicated for the treatment of @entity161 . We analysed adverse events (AEs) reported in primary practice in England. Dispensed prescriptions issued between December 1996 and May 1998 provided exposure data. Questionnaires sent to general practitioners provided outcomes. Frequently reported AEs were: drowsiness/sedation (n = 19), @entity21 (n = 13) and unspecified side-effects (n = 33). Events with highest incidence density in first month and reason for stopping were: drowsiness/sedation [n = 153, incidence density (ID)1 18.9], @entity1017 (n = 117, @entity13863 8.9) and malaise/lassitude (n = 65, @entity13863 5.2). @entity21 were more common in elderly population (> 70 years, @entity13863 3.6, risk 26.0 per 1,000 @entity1 ) compared to < 70 years ( @entity13863 1.1, risk 8.4 per 1,000 @entity1 ). Serious suspected adverse reactions were @entity3326 (n = 1) and angioneurotic ooedema (n = 2). There were eight reports of @entity6 assessed as possibly due to @entity1037 . @entity6 was an unlabelled AE and possible signal generated by prescription-event monitoring.

The pharmacovigilance of XXXX : results of a post-marketing surveillance study on 8858 @entity1 in England.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3326 :: ('MESH:D009459', 'Disease') :: ['neuroleptic malignant syndrome'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus', 'Diabetes mellitus'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity21 :: ('MESH:D001480', 'Disease') :: ['Extrapyramidal disorders', 'extrapyramidal disorder'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['Olanzapine', 'olanzapine'] @entity13863 :: ('3397', 'Gene') :: ['ID1']
@entity1037 :: (MESH:C076029,Chemical) :: ['olanzapine']
